SEC Info - US Oncology Inc - ‘10-K’ for 12/31/03

SEC Info℠

Home

Help

Please Sign In

US Oncology Inc – ‘10-K’ for 12/31/03 – EX-32.1

On: Friday, 3/12/04, at 3:04pm ET · For: 12/31/03 · Accession #: 1193125-4-40388 · File #: 0-26190

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/12/04  US Oncology Inc                   10-K       12/31/03    8:1.2M                                   RR Donnelley/FA

Annual Report — Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for the Period Ended December 31, 2003    HTML   1.02M 
 2: EX-14       Code of Ethics and Business Standards               HTML     59K 
 3: EX-21.1     Subsidiaries of the Registrant                      HTML     14K 
 4: EX-23.1     Consent of Pricewaterhousecoopers LLP               HTML      7K 
 5: EX-31.1     Certification of CEO                                HTML     15K 
 6: EX-31.2     Certification of CFO                                HTML     15K 
 7: EX-32.1     Certification of CEO                                HTML     10K 
 8: EX-32.2     Certification of CFO                                HTML     10K

EX-32.1 — Certification of CEO

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Certification of CEO

US Oncology, Inc.

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of US Oncology, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, R. Dale Ross, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.




Date:	March 12, 2004:	By:	/s/ *R. D*ALE ROSS

			R. Dale Ross, Chief Executive Officer of US Oncology, Inc.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	3/12/04
For Period End:	12/31/03	10-K/A, 5
		List all Filings

↑Top

Filing Submission 0001193125-04-040388 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)